Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Here’s the scoop on IPO versus SPAC (Special Purpose Acquisition Corporation) from Paul Mieyal, life sciences investment guru.
The pair’s lead candidate, TAK-186 (formerly MVC-101), a first-in-class conditionally active T-cell engager, has recently entered the clinic in a Phase I/II study for the treatment of EGFR-expressing solid tumors such as those found in head and neck cancers.
Boston-based ABclonal Biotechnology acquired contract research organization (CRO) Yurogen Biosystems.
Shares of Five Prime Therapeutics were soaring this morning after Amgen announced it was acquiring the company and its Phase III ready anti-FGFR2b antibody bemarituzumab for $1.9 billion in cash.
If Resolution hits specified milestones, it’ll scoop up an extra $145 million from Agilent.
Beijing-based CRMO Pharmaron has accomplished impressive global growth via acquisitions over the past eight months.
The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.
While public perception of the pharmaceutical industry is on an upswing among the general population due to rapid vaccine and therapeutic development during the COVID-19 pandemic, in the eyes of credit rating agencies, the industry is on a continued downward spiral.
Merck said the acquisition adds a pipeline of drug candidates that target a broad range of autoimmune diseases.
CDMO Catalent continues its push to the top with yet another acquisition. Buying out Delphi Genetics, the manufacturing company can now add plasmid DNA production to its growing list of offerings.